Capstone Investment Advisors
RYTM icon

Capstone Investment Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Capstone Investment Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,497
Closed -$353K – 1990
2025
Q3 		$353K Buy
+3,497
New +$325K ﹤0.01% 1570
2024
Q2 		– Sell
-6,738
Closed -$292K – 2415
2024
Q1 		$292K Buy
+6,738
New +$295K ﹤0.01% 1851

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capstone Investment Advisors's RYTM Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 3,497 shares — an estimated $353K sold.

Capstone Investment Advisors first reported a position in RYTM in Q1 2024 and held it in 2 quarters. The position peaked at $353K in Q3 2025. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 3,497 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $353K.
  • Capstone Investment Advisors first reported a position in Rhythm Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Capstone Investment Advisors's Rhythm Pharmaceuticals position peaked at $353K in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.